NCT04876092View on ClinicalTrials.gov

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
Interventions
DRUG

JNJ-67856633

Participants will receive JNJ-67856633 orally.

DRUG

Ibrutinib

Participants will receive Ibrutinib orally.

Trial Locations (10)

2100

Rigshospitalet, Copenhagen

13009

Institut Paoli Calmettes, Marseille

33600

CHU de Bordeaux - Hospital Haut-Leveque, Pessac

44000

CHU de Nantes hotel Dieu, Nantes

59037

CHRU de Lille Hopital Claude Huriez, Lille

75475

Hopital St Louis, Paris

94800

Gustave Roussy, Villejuif

30-727

Pratia MCM Krakow, Krakow

60 185

Centrum Medyczne Pratia Poznan, Skorzewo

221 85

Universitetssjukhuset Lund, Onkologiska Kliniken, Lund, Lund

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04876092 - A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL | Biotech Hunter | Biotech Hunter